ID   TGW
AC   CVCL_1771
SY   TOG; TGW-nu; TGW-I-nu; TGW-nu-1
DR   CLO; CLO_0009830
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 1037
DR   BioSample; SAMN03471635
DR   cancercelllines; CVCL_1771
DR   Cell_Model_Passport; SIDM00324
DR   ChEMBL-Cells; CHEMBL3308792
DR   ChEMBL-Targets; CHEMBL1075600
DR   Cosmic; 801749
DR   Cosmic; 910780
DR   Cosmic; 920238
DR   Cosmic; 947703
DR   Cosmic; 1037349
DR   Cosmic; 1099146
DR   Cosmic; 1153801
DR   Cosmic; 2131589
DR   Cosmic-CLP; 910780
DR   DepMap; ACH-001674
DR   EGA; EGAS00001000978
DR   GDSC; 910780
DR   GEO; GSM314028
DR   GEO; GSM333815
DR   GEO; GSM1670542
DR   JCRB; JCRB0618
DR   LINCS_LDP; LCL-1962
DR   Lonza; 1191
DR   PharmacoDB; TGW_1592_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1771
DR   PubChem_Cell_line; CVCL_1771
DR   Wikidata; Q54972266
RX   PubMed=2335222;
RX   PubMed=12210830;
RX   PubMed=15892104;
RX   PubMed=18923524;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/t/cell-lines-detail-424.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 32 hours (Note=Lot 06012007), ~27 hours (Note=Lot 04172014) (JCRB=JCRB0618).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=71.87%; East Asian, South=26.74%; South Asian=0.97%; European, North=0.42%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Adrenal gland; UBERON=UBERON_0002369.
ST   Source(s): Cosmic-CLP; DepMap; JCRB
ST   Amelogenin: X
ST   CSF1PO: 15
ST   D13S317: 8,11
ST   D16S539: 9,13
ST   D18S51: 14
ST   D21S11: 30,33.2
ST   D3S1358: 16
ST   D5S818: 13
ST   D7S820: 12
ST   D8S1179: 14
ST   FGA: 23
ST   Penta D: 9,10
ST   Penta E: 11,12
ST   TH01: 6,7
ST   TPOX: 10,11
ST   vWA: 14,18
DI   NCIt; C4827; Adrenal gland neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   1Y11M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   PubMed=2335222; DOI=10.1016/0014-5793(90)81370-4;
RA   Tsuchida Y., Sekiguchi M., Kaneko Y., Kanda N.;
RT   "Origin of human neuroblastoma cell lines TGW and TNB1.";
RL   FEBS Lett. 263:191-191(1990).
//
RX   PubMed=12210830; DOI=10.1002/jnr.10330;
RA   Yoshida S., Narita T., Taga T., Ohta S., Takeuchi Y.;
RT   "Malignant rhabdoid tumor shows incomplete neural characteristics as
RT   revealed by expression of SNARE complex.";
RL   J. Neurosci. Res. 69:642-652(2002).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=18923524; DOI=10.1038/nature07399;
RA   Chen Y.-Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M.,
RA   Wang L.-L., Soda M., Kikuchi A., Igarashi T., Nakagawara A.,
RA   Hayashi Y., Mano H., Ogawa S.;
RT   "Oncogenic mutations of ALK kinase in neuroblastoma.";
RL   Nature 455:971-974(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//